NCT06607926View on ClinicalTrials.gov

Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC

NANot yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

October 15, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 30, 2025

Conditions
Resectable Non-Small-Cell Lung Cancer
Interventions
DRUG

Thymosin Alpha 1

4.8 mg subcutaneous injection twice weekly over 12 weeks

DRUG

Tislelizumab

200mg, IV, d1 of each 21-d cycle, four cycles

DRUG

Platinum-doublet chemotherapy

Chemotherapy regimen: (1) for squamous cell carcinoma: cisplatin/carboplatin + paclitaxel; and (2) for non-squamous cell carcinoma: cisplatin/carboplatin + pemetrexed.

Trial Locations (1)

100053

Xuanwu Hospital, Capital Medical University, Beijing

All Listed Sponsors
lead

Xuanwu Hospital, Beijing

OTHER

NCT06607926 - Neoadjuvant With Tα1 Plus Immuno-chemotherapy for Resectable NSCLC | Biotech Hunter | Biotech Hunter